Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
暂无分享,去创建一个
Stephanie A Cohen | O. Olopade | B. Karlan | P. Møller | W. Foulkes | W. Meschino | J. Lubiński | S. Neuhausen | E. Friedman | N. Tung | E. Warner | A. Eisen | C. Singer | S. Narod | J. Kotsopoulos | R. Kim | H. Saal | P. Ainsworth | D. Rayson | T. Pal | K. Metcalfe | A. Poll | R. Demsky | P. Sun | L. Senter | G. Wiesner | C. Cybulski | K. Sweet | R. Yerushalmi | J. Weitzel | M. Wood | C. Snyder | W. McKinnon | O. Ginsburg | T. Huzarski | J. Gronwald | J. McCuaig | J. Blum | D. Zakalik | R. Fruscio | A. Kwong | L. Steele | S. Panchal | S. Randall Armel | C. Elser | C. Cullinane | Stephanie A. Cohen | S. zovato | L. Bordeleau | A. Rastelli | N. Stjepanovic | K. Serfas | J. Dungan | T. R. Y. Cajal | R. E. Reilly | Sophie Sun | Leigha Charis Eng Fergus Robert Jeffrey N. Olufunmilayo C Senter Couch Fruscio Weitzel Olopade Singe | Charis Eng Fergus Couch | Intan Schraeder | Edmond LemireLemire | W. Mckinnon
[1] M. Rué,et al. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. , 2020, European journal of cancer.
[2] A. Degnim,et al. Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. , 2019, Surgery.
[3] L. Rabeneck,et al. Performance measures of magnetic resonance imaging plus mammography in the High Risk Ontario Breast Screening Program. , 2019, Journal of the National Cancer Institute.
[4] B. Karlan,et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers , 2018, JAMA oncology.
[5] W. Chung,et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.
[6] J. Boughey,et al. Mastectomy and Immediate Breast Reconstruction for Cancer in the Elderly: A National Cancer Data Base Study. , 2016, Journal of the American College of Surgeons.
[7] B. Karlan,et al. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers , 2017, Journal of the National Cancer Institute.
[8] S. Narod,et al. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy , 2017, Breast Cancer Research and Treatment.
[9] K. Hunt,et al. Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study , 2017, Annals of Surgical Oncology.
[10] F. Cardoso,et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] A. Howell,et al. Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies , 2014, Journal of Medical Genetics.
[12] Hester F. Lingsma,et al. Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk , 2013, International journal of cancer.
[13] P. Møller,et al. Age‐specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway , 2013, Clinical genetics.
[14] Susan L Neuhausen,et al. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland , 2012, International journal of cancer.
[15] Rosalind Eeles,et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.
[16] J. Oosterwijk,et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age , 2010, Breast Cancer Research and Treatment.
[17] Giovanni Parmigiani,et al. Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] L. Esserman,et al. Genetic/familial high-risk assessment , 2010 .
[19] O. Olopade,et al. Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.
[20] J. Hopper,et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.